DMAC News and Press, DiaMedica Therapeutics Inc. From 01/13/20

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This study is designed to investigate the safety, tolerability and efficacy o...

Gainers:  ASLAN Pharmaceuticals (NASDAQ: ASLN )  +106% . More news on: ASLAN Pharmaceuticals Limited, Can-Fite BioPharma Ltd., SORL Auto Parts, Inc., Stocks on the move, Read more ...

The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with their 2019 Q3 earnings Read more ...

DiaMedica Therapeutics Inc. (DMAC) Q3 2019 Earnings Conference Call November 14, 2019 08:00 ET CompanyParticipants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Thoma...

DiaMedica Therapeutics (NASDAQ: DMAC ): Q3 GAAP EPS of -$0.20 beats by $0.01 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice President of Regulatory Affairs Conference Call with Mana...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13 th . DiaMedica will host a live conference call on Thursday, November 14 th at 7:00 AM Central Time to discuss its ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10 th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, 2019, at the Sheraton New York Times Square Hotel in...

The FDA accepts DiaMedica Therapeutics' (NASDAQ: DMAC ) Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). More news on: DiaMedica Therapeutics Inc., Healthcare stocks news, Read more ...